233 related articles for article (PubMed ID: 24030917)
1. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease.
Krishnaswami S; Chow V; Boy M; Wang C; Chan G
J Clin Pharmacol; 2014 Jan; 54(1):46-52. PubMed ID: 24030917
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
Dowty ME; Lin J; Ryder TF; Wang W; Walker GS; Vaz A; Chan GL; Krishnaswami S; Prakash C
Drug Metab Dispos; 2014 Apr; 42(4):759-73. PubMed ID: 24464803
[TBL] [Abstract][Full Text] [Related]
3. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
Lawendy N; Lamba M; Chan G; Wang R; Alvey CW; Krishnaswami S
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):421-7. PubMed ID: 27129117
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
5. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Krishnaswami S; Boy M; Chow V; Chan G
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
Srinivas N; Barbour AM; Epstein N; Zhou G; Petusky S; Xun Z; Yuska B; Marbury T; Chen X; Yeleswaram S; Punwani N
J Clin Pharmacol; 2020 Aug; 60(8):1022-1029. PubMed ID: 32149388
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
9. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Tse S; Dowty ME; Menon S; Gupta P; Krishnaswami S
J Clin Pharmacol; 2020 Dec; 60(12):1617-1628. PubMed ID: 32592424
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
11. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
Ruperto N; Brunner HI; Zuber Z; Tzaribachev N; Kingsbury DJ; Foeldvari I; Horneff G; Smolewska E; Vehe RK; Hazra A; Wang R; Mebus CA; Alvey C; Lamba M; Krishnaswami S; Stock TC; Wang M; Suehiro R; Martini A; Lovell DJ; ;
Pediatr Rheumatol Online J; 2017 Dec; 15(1):86. PubMed ID: 29282090
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
14. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
Lamba M; Wang R; Fletcher T; Alvey C; Kushner J; Stock TC
J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526
[TBL] [Abstract][Full Text] [Related]
15. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.
Ermer J; Corcoran M; Lasseter K; Marbury T; Yan B; Martin PT
Ther Drug Monit; 2016 Aug; 38(4):546-55. PubMed ID: 26926668
[TBL] [Abstract][Full Text] [Related]
16. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
17. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.
Zomorodi K; Chen D; Lee L; Lasseter K; Marbury T
J Clin Pharmacol; 2019 Aug; 59(8):1120-1129. PubMed ID: 30865315
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
[TBL] [Abstract][Full Text] [Related]
19. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant.
Bergman AJ; Marbury T; Fosbinder T; Swan S; Hickey L; Bradstreet TE; Busillo J; Petty KJ; Aiyer KJ; Constanzer M; Huskey SE; Majumdar A
Clin Pharmacokinet; 2005; 44(6):637-47. PubMed ID: 15910011
[TBL] [Abstract][Full Text] [Related]
20. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
